Abstract 400P
Background
Long non-coding RNAs (LncRNAs) play a critical part in tumor growth and metastasis, but only a small number of LncRNAs are functionally annotated.
Methods
The GEO database was used to analyze breast cancer-related transcriptome data and identify the differentially expressed LncRNA-LINC00294, and qRT-PCR was used to validate the expression of LINC00294 in 30 pairs of breast and para cancer tissues, as well as normal human breast epithelial cells MCF-10A and breast cancer cells MDA-MB-231, SK-BR-3, and MCF-7. The influence of LINC00294 overexpression/interference on the biological properties of breast cancer cells was validated using Western Blot, Transwell, scratch assay, flow cytometry, and CCK-8; the infection of LINC00294 overexpression on the growth of breast tumors in vivo was validated using an in situ tumorigenesis assay in nude mice; the effects of LINC00294 overexpression on the growth of breast tumors in vivo were inquired using Western Blot. The infection of LINC00294 in breast cancer cell biology was investigated by Western Blot, Transwell, scratch assay, and luciferase reporter to investigate the mechanism by which LINC00294 affects breast cancer development via ceRNA adsorption and thus regulates JUP expression.
Results
LINC00294 was significantly upregulated in breast cancer tissues. Furthermore, interference with LINC00294 significantly inhibited breast cancer cell multiplication, invasion, and migration, while overexpression of LINC00294 promoted breast cancer cell invasion proliferation, proliferation, and migration, as well as tumor growth. According to mechanistic studies, LINC00294 could regulate JUP expression and thus the Wnt/β-catenin signaling pathway by targeting miR-485-5p, thus affecting the development of breast cancer.
Conclusions
LINC00294 is highly expressed in breast cancer and may spaciously adsorb miR-485-5p through the ceRNA mechanism to regulate JUP expression, which in turn regulates the Wnt/β-catenin signaling pathway and affects the development of breast cancer. Our findings show that LINC00294 has an effect on breast cancer and identifies a new possible prognostic marker and therapeutic target for this disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
the 'Kuanren meritocrat'Backbone Talents Project of The Second Affiliated Hospital of Chongqing Medical University (no. KY2019G016), Wu Jiping Medical Foundation (no.320.6750.2021-10-86) and Natural Science Foundation of Chongqing, China(no.CSTB2022NSCQ-MSX0055).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
404P - Real-world analysis on molecular targeted therapy recommendations and attainment rates in cancer gene panel testing for metastatic breast cancer
Presenter: Hiroshi Tada
Session: Poster session 15
405P - HRD biomarkers in blood samples from BRCA1/BRCA2-associated advanced breast cancer (BC) patients (pts)
Presenter: Violeta Serra
Session: Poster session 15
406P - Genomic landscape of endocrine therapy (ET)-resistant BRCA1/2 and PALB2 altered metastatic breast cancer (mBC)
Presenter: Abeid Omar
Session: Poster session 15
407P - Genomic profiling and prediction role of the molecular tumor burden index in advanced HR+HER2- breast cancer
Presenter: Xuenan Peng
Session: Poster session 15
408P - Characterizing the genomic landscape of breast cancer in an Irish cohort of patients
Presenter: Georgia Thodi
Session: Poster session 15
409P - Biological tumor traits predicting late recurrence in premenopausal breast cancer patients: Insights from the STO-5 trial with 20-year follow-up
Presenter: Jo De Vos
Session: Poster session 15
410P - Breast cancer lighthouse non-interventional hybrid real-world study: Molecular characterization and 2-year effectiveness data
Presenter: Angela Margarida Nogal Dias
Session: Poster session 15
412P - Exploratory circulating tumor DNA (ctDNA) analysis in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG) in TROPiCS-02
Presenter: Hope Rugo
Session: Poster session 15
413P - Longitudinal circulating tumor DNA (ctDNA) dynamics in phase I/IIa study of the first-in-class CDK4-selective inhibitor, PF-07220060, in combination with endocrine therapy in patients with HR+/HER2− metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors
Presenter: Timothy Anthony Yap
Session: Poster session 15